Enliven Therapeutics (ELVN) CFO Hohl Sells $232K of Stock
Key Points
- Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl sold 6,018 shares on October 19, 2026, under a pre-arranged trading plan.
- After the trade, Benjamin Hohl holds 38,000 $ELVN shares, down 13.67% from before the trade.
- Institutional investors and other insiders have also adjusted their holdings recently ahead of the company's next earnings report.
- Wall Street firms have maintained positive views on the clinical-stage biotechnology firm with several price targets well above recent trading levels.
Since the trade, $ELVN is up 8.1% to date (from the $38.70 close on Oct 19, 2026).
Get Enliven Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $ELVN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Enliven Therapeutics, Inc. alert may contain errors. Disclosures
Inside Benjamin Hohl's Enliven Therapeutics Trade
Enliven Therapeutics, Inc. Chief Financial Officer Benjamin Hohl sold 6,018 shares of the company on October 19, 2026, according to a Form 4 filed with the SEC. The shares were sold at an average price of $38.48 for a total value of $231,545.56. This pre-arranged transaction was executed under a Rule 10b5-1 plan. Following the sale, Hohl directly owns 38,000 shares of the company, cutting his stake by about 13.7%.
ELVN
Enliven Therapeutics, Inc.
Other Institutional Activity in Enliven Therapeutics
Large funds continue to shuffle their positions in the clinical-stage biopharmaceutical firm. Baker Bros. Advisors grew its holdings by 633,785 shares, ending with 905,191 shares worth about $45,938,443.25. Orbimed Advisors LLC. reduced its stake by 1,182,767 shares, leaving it with 6,776,632 shares valued around $283,398,748.0. Polar Capital Holdings PLC added 1,364,750 shares for a total of 6,430,636 shares worth about $268,929,195.0. Vestal Point Capital, LP grew its holdings by 750,081 shares to end with 4,000,000 shares valued at roughly $167,279,998.0. Commodore Capital Lp kept its stake steady, holding 3,275,000 shares worth about $136,960,499.0.
Enliven Therapeutics, Inc. Stock Down 16.6%
Enliven Therapeutics recently traded around $41.25 as of October 21, 2026. That puts the stock up about 10.5% compared to its close of $37.32 on October 16, 2026.
Recent Earnings
The company reported trailing twelve-month earnings per share of -$1.65. Its next corporate earnings release is scheduled for November 11, 2026.
Insider Buying and Selling at Enliven Therapeutics, Inc.
Earlier insider moves include Chief Medical Officer Helen Louise Collins selling 5,000 shares on August 17, 2026, and another 5,000 shares on September 17, 2026. Benjamin Hohl previously sold 6,018 shares on September 17, 2026. Director J Scott Garland also sold 13,000 shares on October 1, 2026, at $46.67 per share for a total value of $606,719.0.
Analysts Set New Price Targets
Wall Street firms have active coverage on the stock. On August 18, 2026, William Blair initiated coverage with an Outperform rating. Barclays also initiated coverage on August 18, 2026, setting an Overweight rating and a $78.0 price target. JP Morgan initiated coverage on October 1, 2026, with an Overweight rating and a $75.0 price target. Morgan Stanley followed on October 2, 2026, with an Overweight rating and a $70.0 price target. HC Wainwright & Co. maintained a Buy rating on October 19, 2026, raising its price target to $73.0 from $65.0.
About Enliven Therapeutics
Enliven Therapeutics, Inc. is a Boulder, Colorado-based clinical-stage biopharmaceutical company focused on discovering and developing small molecule inhibitors to treat various forms of cancer. The company employs 67 people and works to address unmet needs in oncology care.
Bottom Line
Investors will look toward the company's upcoming earnings report on November 11, 2026, for further updates on its drug pipeline and financial health. Insider transactions remain a routine part of executive compensation and portfolio management rather than an indicator of future stock performance.
Related Filing Alerts
Source: Benjamin Hohl's Form 4 filing on $ELVN (Oct 19, 2026). Written by software, not financial advice. How we make alerts